Covera-HS (Verapamil Hydrochloride) - Summary

COVERA-HS SUMMARY

Covera-HS^®
(verapamil hydrochloride)
Extended-Release Tablets
Controlled-Onset

Covera-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist).

Covera-HS is indicated for the management of hypertension and angina.

See all Covera-HS indications & dosage >>

COVERA-HS NEWS HIGHLIGHTS

Published Studies Related to Covera-HS (Verapamil)

Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). [2008.08]

Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. [2008.08]

Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. [2007.11]

Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. [2007.08]

Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). [2007.06.01]

more >>

Clinical Trials Related to Covera-HS (Verapamil)

The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers [Completed]

INVEST: INternational VErapamil SR Trandolapril STudy [Completed]

Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem [Recruiting]

Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy [Recruiting]

Therapy With Verapamil or Carvedilol in Chronic Heart Failure [Recruiting]

more >>